Merck & Co., Inc. (MRK) yesterday, won the US Food and Drug Administration’s (FDA) Accelerated Approval for its breakthrough cancer therapy, Keytruda. It beat Bristol-Myers Squibb Co. (BMY) by becoming the first company first to get approval for a PD-1 inhibitor drug in the US. Keytruda has been approved for the treatment of advanced melanoma in patients who have failed treatments with Bristol-Myers’ Yervoy and other drugs.
By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) meeting, promises to produce longer-lasting remissions.
Eli Lilly and Co (LLY) announced positive results from Phase III RAISE trials on CYRAMZA (Ramucirumab) yesterday, which will be used to treat metastatic Colorectal Cancer (mCRC), in combination with chemotherapy.
By Peter Geschek:In February Merck (MRK) has signed three collaboration agreements with Amgen (AMGN), Incyte (INCY) and Pfizer (PFE), to conduct separate clinical trials combining Merck's anti-PD-1 therapy MK-3475
The European Medicines Agency’s (EMA) advisory committee has given a positive recommendation for a label update of AstraZeneca plc’s (ADR) (AZN) lung cancer drug Iressa. The drug can now be administered to non-small cell lung cancer (NSCLC) patients with an EGFR mutation that is detected through blood-tests rather than a tumor sample.